ID

31873

Description

A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab; ODM derived from: https://clinicaltrials.gov/show/NCT00808210

Lien

https://clinicaltrials.gov/show/NCT00808210

Mots-clés

Versions (1)
  1. 05/10/2018 05/10/2018 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

5 octobre 2018

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Rheumatoid Arthritis NCT00808210

Anglais

Eligibility Rheumatoid Arthritis NCT00808210

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
age >= 18 years
Description

Age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
current treatment for ra on an outpatient basis
Description

Therapeutic procedure Rheumatoid Arthritis | Outpatients

Type de données

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0003873
UMLS CUI [2]
C0029921
active disease
Description

Active disease

Type de données

boolean

Alias
UMLS CUI [1]
C2707252
currently receiving 50 mg etanercept subcutaneously (sc) every week or 40 mg adalimumab sc every other week.
Description

Etanercept Subcutaneous U/week | Adalimumab Subcutaneous U/week

Type de données

boolean

Alias
UMLS CUI [1,1]
C0717758
UMLS CUI [1,2]
C1522438
UMLS CUI [1,3]
C0560588
UMLS CUI [2,1]
C1122087
UMLS CUI [2,2]
C1522438
UMLS CUI [2,3]
C0560588
considered by investigator to be a primary non-responder to their first anti-tnfî±
Description

Therapy non-responder Primary | Anti-tumor necrosis factor alpha drug First

Type de données

boolean

Alias
UMLS CUI [1,1]
C0919875
UMLS CUI [1,2]
C0205225
UMLS CUI [2,1]
C1562242
UMLS CUI [2,2]
C0205435
treatment for efficacy reasons
Description

Therapeutic procedure Efficacy Related

Type de données

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C1280519
UMLS CUI [1,3]
C0439849
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
rheumatic autoimmune disease other than ra, or significant systemic involvement secondary to ra
Description

Autoimmune Disease Rheumatic | Exception Rheumatoid Arthritis | Rheumatoid arthritis with systemic involvement

Type de données

boolean

Alias
UMLS CUI [1,1]
C0004364
UMLS CUI [1,2]
C0035435
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0003873
UMLS CUI [3]
C0494896
history of, or current, inflammatory joint disease other than ra (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, lyme disease) or other systemic autoimmune disorder (e.g., systemic lupus erythematosus, inflammatory bowel disease, scleroderma, inflammatory myopathy, mixed connective tissue disease or other overlap syndrome)
Description

Inflammatory joint disease | Exception Rheumatoid Arthritis | Gout | Arthritis, Reactive | Arthritis, Psoriatic | Spondylarthropathy Seronegative | Lyme Disease | Systemic Autoimmune disease | Lupus Erythematosus, Systemic | Inflammatory Bowel Diseases | Scleroderma | Myositis | Mixed Connective Tissue Disease | Overlap syndrome

Type de données

boolean

Alias
UMLS CUI [1]
C0683381
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0003873
UMLS CUI [3]
C0018099
UMLS CUI [4]
C0085435
UMLS CUI [5]
C0003872
UMLS CUI [6,1]
C0949691
UMLS CUI [6,2]
C0521144
UMLS CUI [7]
C0024198
UMLS CUI [8]
C2895206
UMLS CUI [9]
C0024141
UMLS CUI [10]
C0021390
UMLS CUI [11]
C0011644
UMLS CUI [12]
C0027121
UMLS CUI [13]
C0026272
UMLS CUI [14]
C0410000
previous treatment with a any biologic therapy for ra (including investigational products with the exception of etanercept or adalimumab
Description

Biological treatment Rheumatoid Arthritis | Investigational New Drugs | Exception Etanercept | Exception Adalimumab

Type de données

boolean

Alias
UMLS CUI [1,1]
C1531518
UMLS CUI [1,2]
C0003873
UMLS CUI [2]
C0013230
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0717758
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C1122087
treatment with more than one prior anti-tnfî± therapy
Description

Anti-TNF-alpha therapy Quantity

Type de données

boolean

Alias
UMLS CUI [1,1]
C0281481
UMLS CUI [1,2]
C1265611
Retour au début de la page

Similar models

Eligibility Rheumatoid Arthritis NCT00808210

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
age >= 18 years
boolean
C0001779 (UMLS CUI [1])
Therapeutic procedure Rheumatoid Arthritis | Outpatients
Item
current treatment for ra on an outpatient basis
boolean
C0087111 (UMLS CUI [1,1])
C0003873 (UMLS CUI [1,2])
C0029921 (UMLS CUI [2])
Active disease
Item
active disease
boolean
C2707252 (UMLS CUI [1])
Etanercept Subcutaneous U/week | Adalimumab Subcutaneous U/week
Item
currently receiving 50 mg etanercept subcutaneously (sc) every week or 40 mg adalimumab sc every other week.
boolean
C0717758 (UMLS CUI [1,1])
C1522438 (UMLS CUI [1,2])
C0560588 (UMLS CUI [1,3])
C1122087 (UMLS CUI [2,1])
C1522438 (UMLS CUI [2,2])
C0560588 (UMLS CUI [2,3])
Therapy non-responder Primary | Anti-tumor necrosis factor alpha drug First
Item
considered by investigator to be a primary non-responder to their first anti-tnfî±
boolean
C0919875 (UMLS CUI [1,1])
C0205225 (UMLS CUI [1,2])
C1562242 (UMLS CUI [2,1])
C0205435 (UMLS CUI [2,2])
Therapeutic procedure Efficacy Related
Item
treatment for efficacy reasons
boolean
C0087111 (UMLS CUI [1,1])
C1280519 (UMLS CUI [1,2])
C0439849 (UMLS CUI [1,3])
Item Group
C0680251 (UMLS CUI)
Autoimmune Disease Rheumatic | Exception Rheumatoid Arthritis | Rheumatoid arthritis with systemic involvement
Item
rheumatic autoimmune disease other than ra, or significant systemic involvement secondary to ra
boolean
C0004364 (UMLS CUI [1,1])
C0035435 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0003873 (UMLS CUI [2,2])
C0494896 (UMLS CUI [3])
Inflammatory joint disease | Exception Rheumatoid Arthritis | Gout | Arthritis, Reactive | Arthritis, Psoriatic | Spondylarthropathy Seronegative | Lyme Disease | Systemic Autoimmune disease | Lupus Erythematosus, Systemic | Inflammatory Bowel Diseases | Scleroderma | Myositis | Mixed Connective Tissue Disease | Overlap syndrome
Item
history of, or current, inflammatory joint disease other than ra (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, lyme disease) or other systemic autoimmune disorder (e.g., systemic lupus erythematosus, inflammatory bowel disease, scleroderma, inflammatory myopathy, mixed connective tissue disease or other overlap syndrome)
boolean
C0683381 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0003873 (UMLS CUI [2,2])
C0018099 (UMLS CUI [3])
C0085435 (UMLS CUI [4])
C0003872 (UMLS CUI [5])
C0949691 (UMLS CUI [6,1])
C0521144 (UMLS CUI [6,2])
C0024198 (UMLS CUI [7])
C2895206 (UMLS CUI [8])
C0024141 (UMLS CUI [9])
C0021390 (UMLS CUI [10])
C0011644 (UMLS CUI [11])
C0027121 (UMLS CUI [12])
C0026272 (UMLS CUI [13])
C0410000 (UMLS CUI [14])
Biological treatment Rheumatoid Arthritis | Investigational New Drugs | Exception Etanercept | Exception Adalimumab
Item
previous treatment with a any biologic therapy for ra (including investigational products with the exception of etanercept or adalimumab
boolean
C1531518 (UMLS CUI [1,1])
C0003873 (UMLS CUI [1,2])
C0013230 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0717758 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C1122087 (UMLS CUI [4,2])
Anti-TNF-alpha therapy Quantity
Item
treatment with more than one prior anti-tnfî± therapy
boolean
C0281481 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial